Mitera Biosciences has secured $1.8 million in funding to advance its research and development efforts in immune system modulation. This capital infusion will support the company's focus on Regulatory T cell ("Treg") biology, a critical area for maintaining a healthy and balanced innate immune system.
The company is developing drug candidates derived from a natural human protein, leveraging intellectual property exclusively licensed from Cedars Sinai Medical Center. This protein, naturally produced during pregnancy and expressed in the thymus, has shown potential to upregulate Tregs and impair T effector (Teff) cells. Mitera Biosciences aims to investigate this mechanism as a therapeutic approach for preventing transplant rejection and treating autoimmune diseases, conditions often perpetuated by Teff cells and suppressed by Tregs. The goal is to offer patients effective treatments without the toxicity associated with current immunosuppressant drugs.
This funding round signifies investor confidence in Mitera Biosciences' innovative strategy and the potential impact of its therapeutic candidates. The $1.8 million will be primarily allocated to advancing the company's lead drug candidates through preclinical studies and further exploring this novel axis of immunobiology for additional therapeutic programs.
Looking ahead, Mitera Biosciences plans to utilize this investment to accelerate its development pipeline. The company is committed to progressing its programs towards future clinical studies, with the ultimate aim of bringing forward less toxic and more targeted treatment options for patients suffering from transplant rejection and various autoimmune conditions.
